Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib plus cetuximab ± binimetinib: Subanalysis of BEACON CRC

被引：1
|
作者：
Ng, K. [1 ]
Ciardiello, F. [2 ]
Van Cutsem, E. [3 ,4 ]
Yaeger, R. [5 ]
Yoshino, T. [6 ]
Desai, J. [7 ]
Wasan, H. [8 ]
Alkuzweny, B. [9 ]
Zhang, X. [10 ]
Tabernero, J. [11 ,12 ]
Kopetz, S. [13 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Campania Luigi Vanvitelli, Naples, Italy
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Univ Leuven, Leuven, Belgium
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[8] Imperial Coll London, Hammersmith Hosp, Div Canc, London, England
[9] Pfizer Inc, San Diego, CA USA
[10] Pfizer Inc, New York, NY USA
[11] Vall Hebron Univ Hosp, Barcelona, Spain
[12] Vall Hebron Inst Oncol, Barcelona, Spain
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SO-37
引用
收藏
页码：S372 / S373
页数：2
相关论文
共 50 条
  • [1] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
    Aderka, D.
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Golden, A.
    Edwards, M.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
  • [2] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    [J]. DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [3] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    [J]. ESMO OPEN, 2022, 7 (03)
  • [4] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)
    Velez, L.
    Trevino, T.
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Gollerkeri, A.
    Maharry, K.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S224 - S225
  • [5] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Desai, Jayesh
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 119 - 120
  • [7] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    [J]. ESMO OPEN, 2021, 6 (06)
  • [8] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
    Wasan, Harpreet
    Arkenau, Tobias
    Braun, Mike
    Samuel, Leslie
    Graham, Janet
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    [J]. BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
  • [9] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
    Kato, T.
    Kotani, D.
    Takashima, A.
    Satoh, T.
    Masuishi, T.
    Komatsu, Y.
    Shiozawa, M.
    Esaki, T.
    Izawa, N.
    Takeuchi, S.
    Bando, H.
    Iwasa, S.
    Hasegawa, H.
    Yamaguchi, T.
    Taniguchi, H.
    Yamada, S.
    Yoshino, T.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
  • [10] ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Grothey, A.
    Tabernero, J.
    Taieb, J.
    Yaeger, R.
    Yoshino, T.
    Maiello, E.
    Fernandez, E. Elez
    Casado, A. Ruiz
    Ross, P.
    Andre, T.
    Kato, T.
    Ruffinelli, J.
    Graham, J.
    Van den Eynde, M.
    Vera, R.
    Jean, B.
    Roussel, E. Carriere
    Cahuzac, C.
    Issiakhem, Z.
    Vedovato, J.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S242 - S243
12345